Auxly Cannabis Group Inc. reports developments as a Canadian consumer packaged goods company in the cannabis products market, with securities quoted on the OTCQB under CBWTF and listed on the TSX under XLY. Company news commonly covers quarterly and annual financial results, branded cannabis sales, product innovation, and distribution across Canadian recreational cannabis channels.
Recurring updates focus on product categories such as dried flower, pre-rolls, vapes, oils, and Cannabis 2.0 products, along with brands including Back Forty, Backpackers, and South Point. Auxly also reports capital-allocation actions, balance-sheet changes, issuer bids, debt repayment, and selective strategic financing or transaction activity tied to its cannabis portfolio.
Auxly (OTCQB: CBWTF) reported Q3 2025 results on November 13, 2025. Key metrics: net revenues $39.9M (+20% YoY), Adjusted EBITDA $12.3M (+48% YoY, 31% margin), and net income $20.5M (+533% YoY). Gross margin on finished cannabis inventory sold improved to 56% from 47% a year earlier. Cash at quarter end totaled $30.5M (up 66% YoY). Year-to-date net revenues were $111.4M (+27%) and Adjusted EBITDA $31.2M (+99%).
The company cited higher volumes, improved pricing, manufacturing efficiencies and a gain on the Imperial Debenture settlement as drivers. Auxly plans $2.0–$2.5M of 2025 capex and to prioritize free-cash-flow-funded growth, deleveraging, and potential strategic initiatives.
Auxly Cannabis Group (OTCQB: CBWTF; TSX: XLY) will report third-quarter and nine-month 2025 results for the period ended September 30, 2025 on Thursday, November 13, 2025 before markets open.
The company's regulatory filing, press release and shareholder letter will be available on its website, and shareholders or prospective investors may contact management by the e-mail address provided by the company. The announcement is signed on behalf of the board by Hugo Alves, CEO.
Auxly Cannabis Group (OTCQB: CBWTF, TSX: XLY) announced on Oct 27, 2025 that it repaid in full a $5 million inventory loan owed to GrassHopper Capital using cash on hand. The company expects annualized interest expense savings of approximately $900,000 as a result.
Management said revenue growth and operating leverage have produced free cash flow, allowing Auxly to prioritize organic investment and strengthen the balance sheet by eliminating the loan and reducing recurring interest costs.
Auxly (OTCQB: CBWTF / TSX: XLY) will present at the Planet MicroCap Showcase: Toronto on Wednesday, October 22, 2025 at 11:30 AM EST at Arcadian Loft in Downtown Toronto.
Hugo Alves, Chief Executive Officer, will host the presentation and answer questions. A live webcast will be available via the conference platform under the event Agenda tab. Investors may register for the conference and request 1x1 meetings through the provided registration link.
Auxly Cannabis Group (OTCQB: CBWTF) reported strong Q2 2025 financial results with significant year-over-year improvements. Net revenues reached $38.8 million, up 33% YoY, while gross margin improved to 52% from 41% in Q2 2024. The company achieved net income of $8.3 million, a 315% increase YoY, and Adjusted EBITDA of $11.6 million, representing 30% of net revenue.
The company strengthened its market position as the #3 largest Canadian Licensed Producer with 6.2% market share. Back Forty became the #1 cannabis brand in Canada, with their Liquid Imagination and Fire Breath 28g products leading national sales. Post-quarter, Auxly enhanced its balance sheet through debt amendments and Imperial Brands' debt-to-equity conversion, reducing the pro forma Total Debt to TTM Adjusted EBITDA to 1.4x.
Auxly Cannabis Group (OTCQB:CBWTF) has scheduled its Q2 2025 earnings release for August 14, 2025, before market open. The company will report results for both the second quarter and the six-month period ending June 30, 2025.
The company announced it will not hold an earnings conference call and does not plan to reinstate earnings calls in the near future. Investors are directed to send their inquiries to IR@auxly.com.
Auxly Cannabis Group (OTCQB: CBWTF) has successfully completed two transformative financial transactions that significantly strengthen its balance sheet and financial position. The company has eliminated $21 million in debt and secured an amended credit facility with BMO, which includes a $36.2 million term loan and a $10 million revolving facility.
The company has also settled all obligations with Imperial Brands through a combination of share conversions and warrant issuances. This settlement included converting $1 million principal amount into shares at $0.81 per share, converting $1.39 million of accrued interest into shares at $0.0811 per share, and issuing warrants for 90.8 million shares in exchange for approximately $7.37 million of additional interest, with $11.79 million in remaining interest forgiven.
Alvotech (NASDAQ: ALVO) reported strong Q1 2025 financial results, with total revenues reaching $132.8 million, a 260% increase year-over-year. Product revenues surged 786% to $109.9 million, while Adjusted EBITDA improved to $20.5 million from negative $38.4 million in 2023.
The company increased its full-year guidance to $600-$700 million in revenue and $200-280 million in adjusted EBITDA, following the acquisition of Xbrane's R&D operations and rights to a proposed Cimzia biosimilar. Notable achievements include the U.S. launch of SELARSDI™ (ustekinumab-aekn), a Stelara® biosimilar, and BLA filing acceptances for biosimilars to Simponi®, Eylea®, and Prolia/Xgeva.
The company reported a net profit of $109.7 million ($0.39 per share) and expects to be free cash-flow positive in 2025.